Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Magicell-NK in Stage I/IIa Colon Cancer Post Resection
NCT05394714Phase 1Recruiting
- Sponsor
- Medigen Biotechnology
- Start
- Mar 2022
- Primary completion
- Jun 2028
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Magicell-NK in colon cancer, sponsored by Medigen Biotechnology. Primary endpoints: Number of Participants With Serious Adverse Events (SAEs) and Treatment Emergent Adverse Events (TEAEs) up to 60 weeks, Number of Participants With at Least One Dose Limiting Toxicity up to 60 weeks and 1 more. Started Mar 2022; status: recruiting.
02
Drugs
Magicell-NK
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT05394714.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05394714.